van der Meer M J, Sweep C G, Rijnkels C E, Pesman G J, Tilders F J, Kloppenborg P W, Hermus A R
Department of Medicine, University Hospital Nijmegen, The Netherlands.
J Endocrinol Invest. 1996 Mar;19(3):175-82. doi: 10.1007/BF03349862.
We investigated the effects of i.v. and intracerebroventricular (i.c.v) administration of increasing doses of recombinant human IL-1 beta, TNF alpha and IL-6 on plasma corticosterone (B) levels in rats. Rats were equipped with a jugular cannula for repeated blood sampling anda subgroup of rats also received an i.c.v implanted cannula. I.v. administration of IL-1 beta, TNF alpha or IL-6 and i.c.v administration of IL-1 beta and IL-6 induced a significant dose-dependent increase in plasma B levels, whereas i.c.v injection of TNF alpha in doses up to 1000 ng/rat was not effective. I.v. pretreatment of rats with anti-CRH antiserum had no significant overall effect on the plasma B response to i.v. administered IL-1 beta (500 and 3000 ng/rat), whereas the plasma B response to i.v. TNF alpha or IL-6 administration (3000 ng/rat) were significantly reduced. I.v. pretreatment of the animals with recombinant human IL-1 receptor antagonist (IL-1ra) significantly blocked the plasma B response to i.v. treatment with IL-1 beta, whereas the TNF alpha- and IL-6-induced increases in plasma B levels were not affected. Our data show that 1) i.v. administration of IL-beta, TNF alpha or IL-6 and i.c.v administration of IL-1 beta or IL-6 dose-dependently stimulate the HPA axis; 2) when given i.v. or i.c.v, IL-1 beta is more powerful than TNF alpha and IL-6 in activating the HPA axis; 3) endogenous CRH is involved in the activation of the HPA axis by acute i.v. administration of TNF alpha and IL-6. It is most likely that in case of i.v. treatment with IL-1 beta a CRH-independent mechanism is involved. This study provides no arguments for the involvement of endogenous IL-1 in TNF alpha- or IL-6-induced activation of the HPA axis.
我们研究了静脉注射(i.v.)和脑室内(i.c.v.)给予递增剂量的重组人白细胞介素-1β(IL-1β)、肿瘤坏死因子α(TNFα)和白细胞介素-6(IL-6)对大鼠血浆皮质酮(B)水平的影响。给大鼠安装颈静脉插管以便重复采血,并且一组大鼠还接受了脑室内植入插管。静脉注射IL-1β、TNFα或IL-6以及脑室内注射IL-1β和IL-6均能引起血浆B水平显著的剂量依赖性升高,而脑室内注射高达1000 ng/大鼠剂量的TNFα则无效。用抗促肾上腺皮质激素释放激素(CRH)抗血清对大鼠进行静脉预处理,对静脉注射IL-1β(500和3000 ng/大鼠)引起的血浆B反应总体上没有显著影响,而对静脉注射TNFα或IL-6(3000 ng/大鼠)引起的血浆B反应则有显著降低。用重组人白细胞介素-1受体拮抗剂(IL-1ra)对动物进行静脉预处理,可显著阻断静脉注射IL-1β引起的血浆B反应,而TNFα和IL-6引起的血浆B水平升高则不受影响。我们的数据表明:1)静脉注射IL-β、TNFα或IL-6以及脑室内注射IL-1β或IL-6能剂量依赖性地刺激下丘脑-垂体-肾上腺(HPA)轴;2)静脉或脑室内给药时,IL-1β在激活HPA轴方面比TNFα和IL-6更有效;3)内源性CRH参与急性静脉注射TNFα和IL-6对HPA轴的激活。静脉注射IL-1β时很可能涉及一种不依赖CRH的机制。本研究没有提供内源性IL-1参与TNFα或IL-6诱导的HPA轴激活的证据。